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Abstract
Mammalian bile acids (BAs) are oxidized metabolites of cholesterol whose amphiphilic properties serve in lipid and
cholesterol uptake. BAs also act as hormone-like substances that regulate metabolism. The Caenorhabditis elegans clk-1
mutants sustain elevated mitochondrial oxidative stress and display a slow defecation phenotype that is sensitive to the
level of dietary cholesterol. We found that: 1) The defecation phenotype of clk-1 mutants is suppressed by mutations in tat-2
identified in a previous unbiased screen for suppressors of clk-1. TAT-2 is homologous to ATP8B1, a flippase required for
normal BA secretion in mammals. 2) The phenotype is suppressed by cholestyramine, a resin that binds BAs. 3) The
phenotype is suppressed by the knock-down of C. elegans homologues of BA–biosynthetic enzymes. 4) The phenotype is
enhanced by treatment with BAs. 5) Lipid extracts from C. elegans contain an activity that mimics the effect of BAs on clk-1,
and the activity is more abundant in clk-1 extracts. 6) clk-1 and clk-1;tat-2 double mutants show altered cholesterol content.
7) The clk-1 phenotype is enhanced by high dietary cholesterol and this requires TAT-2. 8) Suppression of clk-1 by tat-2 is
rescued by BAs, and this requires dietary cholesterol. 9) The clk-1 phenotype, including the level of activity in lipid extracts, is
suppressed by antioxidants and enhanced by depletion of mitochondrial superoxide dismutases. These observations
suggest that C. elegans synthesizes and secretes molecules with properties and functions resembling those of BAs. These
molecules act in cholesterol uptake, and their level of synthesis is up-regulated by mitochondrial oxidative stress. Future
investigations should reveal whether these molecules are in fact BAs, which would suggest the unexplored possibility that
the elevated oxidative stress that characterizes the metabolic syndrome might participate in disease processes by affecting
the regulation of metabolism by BAs.
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Introduction
In mammals, cholesterol is necessary for the structure and
function of membranes, and is the substrate for the biosynthesis of
signalling molecules such as sexual steroids, bioactive compounds
such as vitamin D, and bile acids (BAs) [1]. Cholesterol is
converted into BAs through a series of oxidation reactions, as well
as a shortening of the side chain in mammals (Figure S1). The
enzymes that catalyze the individual biosynthetic steps of BA
synthesis are localized in different cellular compartments,
including the endoplasmic reticulum, cytosol, mitochondria, and
peroxisomes. For example, the oxidation of the side-chain takes
place in the mitochondria, but side-chain shortening takes place in
the peroxisomes. In vertebrates, these reactions occur predomi-
nantly in hepatocytes.
BAs regulate cholesterol and lipid metabolism in a variety of
ways. They participate in cholesterol, lipid and hydrophobic
vitamin uptake through their properties as detergents. They also
participate in cholesterol elimination as they are secreted into the
gut from where a fraction is lost every day in the feces. However,
most of the secreted BAs are taken up again through the gut
epithelium and can be re-circulated to the liver and re-secreted
into bile, a process that is called the entero-hepatic circulation of
BAs. In addition, BAs are signalling molecules that integrate
several aspects of metabolism, including fat, glucose, and energy
metabolism by regulating gene expression through nuclear
hormone receptors such as the farnesoid X receptor (FXR), the
pregnane X receptor (PXR), and the vitamin D receptor (VDR)
(BA biology is reviewed in detail in [2,3]).
In mammals, BA excretion and recirculation depend on a
number of membrane transporters such as ATP8B1 and ABCB11.
ATP8B1, a type 4 P-type ATPase is a predicted phospholipid
flippase [4]. Flippases transfer lipids from one leaflet of the
membrane to the other thus changing the composition of both
leaflets and the properties of the membranes. Several studies in
mice suggest that ATP8B1 deficiency causes loss of canalicular
membrane phospholipid asymmetry and as a result the resistance
of the canalicular membrane to hydrophobic BAs is decreased,
which impairs the activity of ABCB11, the BA export pump, and
causes cholestasis, a pathological retention of bile [5]. Mutation of
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cholestasis type 1 (PFIC1) [6].
ATP8B1 shares 56% sequence identity with C. elegans TAT-2
(for Transbilayer Amphipath Transporters) [4,7,8]. A tat-2 mutant
was found to exhibit hypersensitivity to low dietary cholesterol
with decreased reproductive growth [8]. tat-2 mutation also sup-
presses the conditional growth arrest phenotypes resulting from
mutation of elo-5, a gene encoding a very long chain fatty acid
(VLCFA) elongase, which is required for the production of two
monomethyl branched-chain fatty acids (mmBCFAs) in C. elegans
[7]. As tat-2 also partially suppresses developmental defects caused
by reduction of the expression of sptl-1, which disrupts sphingo-
lipid biosynthesis, the authors proposed that TAT-2 acts by
affecting the localization of mmBCFA-containing sphingolipids.
Like vertebrates, C. elegans need sterols (reviewed in [9]).
However, as C. elegans is capable only of modifying sterols and
not of synthesising them de novo, worms are auxotrophic for
sterols, which have to be added to the culture media (generally at
5 mg/ml cholesterol). A reduction in sterol supplementation leads
to a complex phenotype that includes abnormal moulting, and
inappropriate dauer formation. A complete lack of sterol
supplementation leads to lethality. As sterols appear to be required
only in very small amounts for normal physiology in worms, the
deficit resulting from the absence of dietary cholesterol might
result from deficits in the synthesis of signalling molecules derived
from cholesterol. Indeed BA-like molecules derived from choles-
terol have been identified in C. elegans and shown to have roles in
signalling [10]. Dafachronic acid, which is required for bypassing
dauer formation, has some characteristics of BAs, with oxidation
of the steroid ring and of the side-chain, but its oxidation is not
extensive and the side-chain is not shortened [10]. Yet, like
vertebrate steroids and BAs, it acts via a nuclear hormone
receptor, encoded by daf-12 [10].
In mammals, after BA-mediated absorption, ingested lipids,
cholesterol, and lipid-soluble vitamins, are transported from the
gut to the tissues that need them via circulating lipoproteins such
as chylomicrons. Other lipoproteins such as low density lipopro-
teins (LDL) distribute lipids and cholesterol from the liver to
peripheral tissues, and high density lipoproteins (HDL) transport
cholesterol from peripheral tissues back to the liver in a process
termed reverse cholesterol transport. The best known lipoproteins
in C. elegans are the yolk particles. The protein moieties of yolk
particles are vitellogenins, distant homologues of ApoB, which is
the apolipoprotein in chylomicrons and LDL [11]. In C. elegans,
cholesterol, fatty acids, and possibly other nutrients are transport-
ed from the gut to developing oocytes through the pseudocoelomic
cavity by means of yolk particles [12,13]. However, several
observations suggest that there is another lipid transport system in
worms [14]. For example, hermaphrodites are capable of
transporting cholesterol before the vitellogenins are expressed
and males do not express vitellogenins yet accumulate cholesterol
in developing sperm [13]. Furthermore, a mutation in dsc-4, which
encodes the worm homologue of the microsomal triglyceride
transfer protein (MTP) [15], which is required in mammals for the
synthesis of LDL in the ER, produces multiple phenotypic effects
without affecting yolk production.
CLK-1 is a conserved mitochondrial enzyme that is necessary
for the biosynthesis of the antioxidant and redox cofactor
ubiquinone (co-enzyme Q; CoQ). Mutations in C. elegans clk-1 or
its mouse orthologue affect mitochondrial function [16,17], in
particular they increase mitochondrial oxidative stress in both
organisms [18,19]. In worms, this results in a number of
phenotypes, in particular slow development, slow aging, and slow
rhythmic behaviours such as defecation [20].
The defecation cycle of C. elegans generates rhythmic body
muscle contractions. This is a well-studied, highly regulated
behaviour that is readily quantifiable [21]. dsc-4/mtp was originally
identified as a mutation that suppresses the slow defecation of clk-1
mutants [22]. Given the known function of MTP it was concluded
that a type of MTP-dependent, LDL-like lipoprotein, distinct from
yolk, affects the rate of defecation [14]. Reducing the level of
dietary cholesterol mimics the effects of dsc-4 on the defecation
cycle length of clk-1 mutants [15,23]. These observations suggest
that clk-1 mutants have slow defecation because they have high
levels of LDL-like lipoproteins biosynthesis and secretion.
Furthermore, the MTP-dependent lipid transport system appears
to be so well conserved between mammals and C. elegans that drugs
that have been developed to lower lipid levels in humans can act as
suppressors of the slow defecation rate of clk-1 [23]. In particular,
the slow defecation is suppressed by drugs that antagonize high
LDL levels by increasing HDL levels (e.g. an inhibitor of the HDL
receptor SR-BI [24]), or that reverse cholesterol transport by
stimulating gene expression through nuclear hormone receptors
(e.g. gemfibrozil [25]). Thus, although it is not yet known how
elevated lipoprotein biosynthesis slows down the defecation cycle,
the clk-1 mutants provide a tractable genetic model for char-
acterizing the mechanisms of lipids and sterol uptake and the
biosynthesis and secretion of LDL-like lipoproteins.
Here, using genetic and pharmacological approaches, we show
that sterol uptake in C. elegans depends on molecules that are
functionally similar to BAs and might be structurally similar as
well. These molecules are distinct from dafachronic acids and are
synthesized and secreted through a pathway that appears to be
molecularly very similar to that of BA synthesis and secretion in
mammals. We also show that this pathway is altered by the high
mitochondrial oxidative stress of clk-1 mutants. A link of oxidative
stress and aging with dyslipidemia and with the other cardiovas-
cular risk factors that constitute the metabolic syndrome has
repeatedly been evidenced in mammals, but its mechanistic basis
has not yet been elucidated. Our findings suggest that the link
Author Summary
Cholesterol metabolism, in particular the transport of
cholesterol in the blood by lipoproteins, is an important
determinant of human cardiovascular health. Bile acids are
breakdown products of cholesterol that have detergent
properties and are secreted into the gut by the liver. Bile
acids carry out three distinct roles in cholesterol metab-
olism: 1) Their synthesis from cholesterol participates in
cholesterol elimination. 2) They act as detergents in the
uptake of dietary cholesterol from the gut. 3) They
regulate many aspects of metabolism, including choles-
terol metabolism, by molecular mechanisms similar to that
of steroid hormones. We have found that cholesterol
uptake and lipoprotein metabolism in the nematode
Caenorhabditis elegans are regulated by molecules whose
activities, biosynthesis, and secretion strongly resemble
that of bile acids and which might be bile acids. Most
importantly we have found that oxidative stress upsets the
regulation of the synthesis of these molecules. The
metabolic syndrome is a set of cardiovascular risk factors
that include obesity, high blood cholesterol, hypertension,
and insulin resistance. Given the function of bile acids as
metabolic regulators, our findings with C. elegans suggest
the unexplored possibility that the elevated oxidative
stress that characterizes the metabolic syndrome may
participate in mammalian disease processes by affecting
the regulation of bile acid synthesis.
Bile Acid-Like Pathway in C. elegans
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not yet been explored in mammals.
Results
The defecation phenotype of clk-1 is suppressed by tat-2
We previously carried out a genetic screen to find suppressors of
the slow defecation phenotype of clk-1 mutants [22]. In this screen
we identified the dsc-4/mtp mutation (described in the Introduc-
tion) as well as another mutation, dsc-3(qm179), which produced a
very similar phenotype [22]. As the effects of dsc-4/mtp and dsc-
3(qm179) are not additive (Table S1), they may act in a common
pathway or affect a common process. We mapped dsc-3(qm179)
between dpy-13 and unc-5 on LG IV [22]. Using the hypotheses
that dsc-3 is involved in lipoprotein metabolism (based on the
identity of dsc-4/mtp) we identified tat-2 as a candidate gene in that
chromosomal region. We determined that qm179 is allelic to tat-
2(tm1634) based on the following experiments, whose results are
shown in full in Table S1 (Table S1 lists all numerical values,
samples sizes and statistical analyses for all defecation data shown
in figures or mentioned in the text). Firstly, both RNAi against tat-
2 and the deletion mutation of tat-2(tm1634) were phenotypically
similar to qm179 in both the wild type and clk-1 backgrounds.
Secondly, the tat-2(tm1634) deletion mutation fails to complement
qm179 (Figure 1A). Thirdly, transgenic expression of tat-2 rescues
the suppression of clk-1 by qm179 (Figure 1A). Finally, a G-to-A
point mutation that results in an amino acid change from Alanine
to Threonine at residue 665 of the protein was found by
sequencing the coding region of tat-2 in qm179 mutants
(Figure 1B). We name the gene tat-2 from this point on. The
allele analyzed is always qm179 except when otherwise specified.
ATP8B1and TAT-2 are functional homologues
The high sequence conservation between TAT-2 and ATP8B1
suggests that their functions could be conserved as well. To test this
directly we introduced a cDNA coding for mouse ATP8B1 in clk-
1;tat-2 mutants under the C. elegans tat-2 promoter (Figure 1C).
This could partially rescue the suppression of the defecation
phenotype, and was abolished by RNAi against the mouse gene
sequence (Figure 1C). Moreover, rescue by the mouse Atp8b1 gene
was also prevented by introduction of mutations corresponding to
either the tat-2(qm179) mutation or the human G308V mutation
(Table S1), strongly indicating a functional conservation.
TAT-2 is required in the gut for its effect in clk-1 mutants
In order to determine the focus of action of tat-2, we constructed
a reporter gene in which the tat-2 gene with 3.4 kb of upstream
promoter sequence was fused in frame to gfp. This construct was
capable of rescuing the defecation phenotype of tat-2(qm179) in the
clk-1 background (Table S1). The fusion protein was expressed in
the gut, spermatheca, proximal gonad, vulva, excretory cell,
excretory gland cell, pharyngeal procorpus, the pharyngeal-
intestinal valve and the rectal gland cell (Figure S2), which is
consistent with what was previously found by others [7,8]. We also
constructed three other reporters in which 3.4 kb of the tat-2
promoter were replaced by the promoters from the intestinal
specific ges-1, spermatheca-specific sth-1, or excretory canal-
specific pgp-12, genes. Only the Pges-1::tat-2::gfp construct could
rescue the phenotype (Table S1).
The bile acid–binding resin cholestyramine suppresses
the slow defecation of clk-1 mutants
Given the known function of ATP8B1 in bile acid secretion in
mammals (see Introduction), and the fact that eliminating the
function of tat-2 suppresses clk-1, we wondered whether a
pharmacological agent that targets BAs could also suppress
clk-1. Cholestyramine is a BA-binding resin that is taken orally
by people to lower the availability and thus the re-absorption
of BA in the gut, which ultimately results in lowering in the level
of circulating LDL [26]. We found that addition of 0.025%
cholestyramine to worm plates partially suppresses the slow
defecation cycle of clk-1 mutants (Figure 2A). Cholestyramine
had no effect on the wild type or on isp-1 mutants, which, like clk-1
mutants, have mitochondrial defects and a slow defecation cycle
[27]. There was also no effect on tat-2 or dsc-4/mtp mutants (Table
S1). Cholestyramine can bind organic molecules of intermediate to
low polarity that bear an acidic group. This supports the
hypothesis that C. elegans secretes molecules that have chemical
properties resembling those of BAs and that the altered defecation
cycle of clk-1 mutants is due to enhanced secretion of such
molecules.
Suppression by depletion of homologues of
BA–biosynthetic enzymes
We reasoned that if there are mammalian-like BAs in worms
they might be synthesized by enzymes that are similar to those in
mammals. Reducing BA synthesis by depleting such enzymes by
RNAi knock-down should suppress clk-1, similar to the effect of tat-
2 mutations and cholestyramine treatment. The biosynthesis of
BAs in mammals is complex and involves a variety of enzymatic
steps carried out in diverse cellular compartments [1]. In order to
determine if BA-like molecules are synthesised in a similar manner
in worms, we examined 17 of the most common of these steps by
identifying the best C. elegans homologues of the mammalian
enzymes, and testing their impact on the defecation cycle of clk-1
mutants by RNAi (Table 1). Six of these enzymes are part of the
same class of proteins, the P450 oxidases. As all the C. elegans
proteins of this class are more or less equally similar to each of the
vertebrate proteins, we tested all those we found by homology
searching (78 genes). For other classes we tested several of the most
homologous proteins (Table 1). Some classes of homologues did
not have any effect on the defecation phenotype of clk-1 mutants,
e.g. 3b-hydroxy-D5-C27 steroid oxidoreductase, 2-methylacyl-
CoA racemase, and bile acid CoA: amino acid N-acyltransferase.
However, thirteen P450 enzymes as well as worm genes encoding
proteins that are highly similar to mammalian branched-chain
acyl-CoA oxidase and 3a-hydroxysteroid dehydrogenase, choles-
terol 25-hydroxylase, bile acid CoA ligase, the D-bifunctional
protein, and the two genes (daf-22 and nlt-1) that separately encode
the two activities of mammalian peroxisomal thiolase, were
effective in affecting the defecation cycle of clk-1 mutants
(Table 1), suggesting that they may participate in the biosynthesis
of BA-like molecules. Note that RNAi against daf-9/cyp-22A1 and
hsd-1, which encode activities that are known to participate in the
synthesis of dafachronic acids, did not affect clk-1 defecation
(Table 1). daf-12, the nuclear receptor target of dafachronic acids,
was also knocked down by RNAi under the same conditions as the
enzymes: it produced only a very small, not significant,
suppression (22.863.9 seconds (P=0.4795); n=27 for the
control, n=38 for daf-12(RNAi)). Interestingly, in addition to
suppressors of the phenotype, we also obtained a few enhancers,
mostly among the P450s (Table 1). P450s in mammals have
numerous functions besides BA synthesis, and thus have the
potential to affect the rate of defecation in ways unrelated to the
synthesis of BA-like molecules. This is consistent with the
observation that most genetic changes that affect defecation tend
to slow it down [21].
Bile Acid-Like Pathway in C. elegans
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molecules affected by TAT-2 and cholestyramine are
cholesterol derivatives
DAF-36 is a Rieske oxygenase that acts as a cholesterol 7-
desaturase that converts cholesterol to 7-dehydrocholesterol [28,29].
DAF-36 is necessary for dafachronic acid biosynthesis, which is why
mutationofdaf-36leadstoadauerconstitutivephenotype.Wefound
that daf-36(k114) alsosuppresses the slow defecation cycle of clk-1 (by
19.4 seconds), with only a very small effect (1.5 seconds) on the wild
type (Table S1). This is consistent with the hypothesis that the active
molecules that are transported by TAT-2 and are bound by
cholestyramine could be oxidized cholesterol derivatives, although
they are clearly distinct from dafachronic acids (see above).
clk-1 mutants but not wild-type animals are sensitive to
exogenous BAs
Lowering the level of the hypothetical BA-like molecules by
reducing their secretion via mutation of tat-2, reducing their
biosynthesis by RNAi or mutations against potential biosynthetic
enzymes,or bysequestrationthrough cholestyramine suppresses the
clk-1 phenotype. We reasoned that the phenotype might therefore
be enhanced by BA supplementation. We treated clk-1 mutants with
mixed mammalian BAs and found that their phenotype was indeed
enhanced whilethe wild typewas completely insensitive (Figure 2B).
These findings show that externally applied BAs can act on C.
elegans. It also suggests that in the wild type the processes that are
affected by BAs and that ultimately determine the defecation cycle,
such as cholesterol handling (see below) and lipoprotein metabolism
(see Introduction), are better regulated than in clk-1 mutants.
The effects of exogenous BAs depend on their structures
In mammals, BAs of different structures have been found to
interact differently with nuclear hormone receptors thus affecting
differently the regulation of BA synthesis and secretion, and also to
be more or less efficient in cholesterol uptake [2]. In particular,
more hydrophobic BAs appear to result in greater cholesterol
uptake [30]. To test whether the structures of the BAs are
important for their effects on clk-1 mutants we treated the wild
type and clk-1 mutants with three concentrations of cholic acid
(CA), one of the main relatively hydrophilic mammalian BA, and
chenodeoxycholic acid (CDCA), one of the main relatively
hydrophobic mammalian BA. No treatment had any effect on
the wild type (Table S1). However, at two concentrations
(0.15 mM and 0.6 mM), CA suppressed the defecation cycle of
clk-1 mutants, although it enhanced the phenotype at 2.5 mM,
while CDCA enhanced the phenotype in a dose-dependent
manner at all concentrations tested (Figure 2C). One possibility
to explain the ability of CA to suppress clk-1 suggests that it might
be more hydrophilic than the average BA-like molecules secreted
by worms, thus effectively diluting their strength in taking up
cholesterol. This notion is also supported by the observation that
CA was a better suppressor at lower (0.15 mM) than at the higher
(0.6 mM) concentration, and enhanced the phenotype at the
highest concentration (2.5 mM). This suggests that at the higher
concentrations the greater amount of BA (here CA) provided by
the treatment in part compensates for the fact that CA is a more
hydrophilic BA. CDCA had no effect at the lowest concentration
but enhanced the phenotype at higher concentrations (Figure 2C).
An activity that alters the defecation cycle of clk-1
mutants but not that of the wild type can be extracted
from C. elegans and is more abundant in clk-1 mutants
The results presented above suggest that C. elegans produces and
secretes molecules with BA-like properties, and possibly structures,
and that this process is deregulated in clk-1 mutants. We reasoned
that the hypothetical endogenous BA-like molecules should have
the same effect on the wild type and clk-1 mutants as exogenous
BAs. To test this we made lipid extracts [31] from both the wild
type and clk-1 mutants and assayed them on the defecation cycle of
both genotypes. The lipid extracts were applied to plates in the
same way as BAs in previous experiments. Extracts from both
genotypes had no effect on the defecation of the wild type.
However, extract from clk-1 mutants at 0.02 and 0.1 mg sig-
nificantly enhanced the phenotype of clk-1 mutants (Figure 2D). At
these concentrations wild type extracts had no significant effect on
the mutants. Thus to establish that the wild type also contains the
activity, and to measure how much higher the activity was in clk-1
mutants, we produced a large quantity of extract from the wild
type, which allowed to test 0.4 mg of activity on the wild type and
clk-1. The high concentration of wild type extract was again
ineffective on wild type animals but enhanced the phenotype of
clk-1 as much as 0.1 mg of extract from clk-1 (Figure 2D). We
conclude that both the wild type and clk-1 mutants contain the
activity but that clk-1 mutants contain approximately 46 time
higher steady-state levels of the activity.
clk-1 and clk-1;tat-2 mutants show altered cholesterol
content
One of the functions of BAs is to regulate cholesterol uptake and
handling. We therefore measured the level of cholesterol in the
wild type and in clk-1 mutants grown under low (2 mg/ml),
standard (5 mg/ml) and high (50 mg/ml) levels of cholesterol
supplementation. Both the wild type and clk-1 mutants grown on
high cholesterol contained significantly more cholesterol than
when grown under standard conditions (Figure 3A). However the
increase was significantly greater in clk-1 mutants. There was no
Figure 1. qm179 is allelic to tat-2, which encodes a protein homologous to mammalian ATP8B1. (A) Both the qm179 and tat-2(tm1634)
deletion mutation show a short defecation cycle in the wild type background and suppress the slow defecation of clk-1(qm30) mutants in double
mutant combinations. Furthermore the tat-2(tm1634) deletion mutations fails to complement qm179 in both the wild type and clk-1 backgrounds.
The bars represent the mean defecation cycle of animals that have been scored for three consecutive defecation cycles each in the case of clk-
1(qm30) mutants and for five consecutive defecation cycles for all other genotypes. The error bars represent S.E.M. (n$20 animals for each genotype).
The asterisks indicate that the data are significantly different from that of wild-type or clk-1 mutants. All differences were significant at P,0.0001 by a
t-test. (B) Schematic representation of the tat-2 coding region and the lesions of the two alleles. TAT-2 is a membrane protein with 8 predicted
transmembrane domains (red) and several consensus domains for all classes of P-type ATPases (blue) or specific for the P4 P-type ATPase (green). One
of the P4 P-type ATPase-specific consensus domains harbors the residue that is changed in the qm179 allele (alanine 665 to threonine). This residue
(indicated by an asterisk) is absolutely conserved among mammalian ATP8B1, C. elegans TAT-1, and yeast DRS2. Residues that are not perfectly
conserved in this region are underlined. (C) The suppression of clk-1 produced by the tat-2(qm179) mutation can be partially rescued by transgenic
expression of a cDNA coding for the mouse homologue ATP8B1 under the control of the endogenous tat-2 promoter (Ptat-2::mAtp8b1). Treating clk-
1(qm30); tat-2(qm179) mutants that harbor the Ptat-2:mAtp8b1 construct with RNAi against mAtp8b1 abolished the rescue but had no effect by itself.
The bars represent the mean defecation cycle of animals that have been scored for five consecutive defecation cycles. The error bars represent S.E.M.
(n$20 animals for each genotype). Differences were tested by a t-test; * represents P,0.05.
doi:10.1371/journal.pgen.1002553.g001
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tion for either genotype. We also assayed the cholesterol content of
tat-2 and clk-1;tat-2 mutants. The cholesterol content of tat-2 was
similar to that of the wild type at all levels of cholesterol
supplementation. However the increase of cholesterol content
observed in clk-1 mutants under high cholesterol supplementation
was fully abolished in clk-1;tat-2 double mutants (Figure 3A and
Table S2). Furthermore, cholesterol content in the double mutants
was elevated at low and standard level of supplementation and
thus similar at all levels of cholesterol supplementation, indicating
that clk-1 and tat-2 interact in determining the level of cholesterol
uptake and content.
The clk-1 phenotype is sensitive to high cholesterol
supplementation in a tat-2–dependent manner
We have previously shown that the defecation cycle of clk-1
mutants, but not that of the wild type, is suppressed by lowering
the levels of dietary cholesterol from 5 mg/ml to 2 mg/ml [23]. We
have now extended this observation to the effect of high
cholesterol (50 mg/ml), which has no effect on the wild type but
further slows down the defecation of clk-1(qm30) mutants
(Figure 3B). We had observed (Figure 3A) that clk-1 and tat-2
interact in determining the level of cholesterol uptake. We
therefore wondered if the metabolism of the BA-like molecules
was involved in these effects of the level of dietary cholesterol on
the defecation cycle. We found that low cholesterol shortened the
defecation cycle of clk-1;tat-2, but that the effect of high cholesterol
on clk-1 mutants was fully suppressed in clk-1;tat-2 mutants
(Figure 3B). The observation that altering the level of media
cholesterol can affect the defecation phenotype of clk-1 mutants in
both directions suggests that uptake or subsequent handling of
cholesterol can change the phenotype caused by the deregulated
metabolism of the BA-like molecules in clk-1 mutants.
Exogenous BAs rescue tat-2 and enhance clk-1 in a
cholesterol-dependent manner
The results described above suggest that the suppression
produced by the tat-2 mutation might be due to lower secretion
of the BA-like molecules. To test this directly we treated tat-2 and
clk-1;tat-2 mutants with a small amount (0.015%) of mixed
mammalian BAs (Figure 2E and Table S1). These exogenous
BAs had no effect on the wild type or dsc-4 mutants but rescued the
tat-2 phenotype in both the wild-type and clk-1 backgrounds.
Furthermore, these effects of the exogenous BAs were abolished in
the absence of cholesterol supplementation (Figure 2E). We also
found that the effects of BAs we have previously observed, such as
suppression and enhancement of clk-1 by pure CA or CDCA at
various concentrations require cholesterol supplementation
(Figure 2C). These results indicate: 1) that the effect of tat-2 on
clk-1 mutants is mediated by a reduction in the secretion of BA-like
molecules; and 2) that the effects of BAs and tat-2 on clk-1 mutants
implicate changes in cholesterol uptake.
Mitochondrial oxidative stress is responsible for the slow
cycle of clk-1 mutants
We have shown above that the phenotypes of clk-1 mutants
include deregulated metabolism of BA-like molecules, which
results in altered cholesterol content and abnormal sensitivity to
the level of cholesterol supplementation. Previous studies of clk-1
indicated that the principal cellular defect of these mutants is an
elevated level of mitochondrial oxidative stress, characterized by
elevated mitochondrial ROS production [18], elevated oxidative
damage [32,33], and increased sensitivity to pro-oxidant drugs
[34]. In addition, several of the clk-1 phenotypes are strongly
enhanced when the expression of the main mitochondrial
superoxide dismutase (SOD-2) is reduced by RNAi [32] or
mutation [33]. In fact defecation was among the phenotypes that
were found to be enhanced in the clk-1;sod-2 double mutants [33].
To further explore the link between ROS and the clk-1
defecation phenotype we first determined whether RNAi against
the other C. elegans sod genes had any effect. We found that in
addition to sod-2, RNAi knockdown of sod-3, the gene encoding the
other mitochondrial superoxide dismutase, enhanced the defeca-
tion phenotype of clk-1 (Figure 4A). However, RNAi against the
three non-mitochondrial sod genes (sod-1, sod-4, and sod-5) did not
affect the phenotype (Figure 4A), indicating that the enhancement
of the phenotype is specific to alterations in mitochondrial ROS
levels. Consistent with previous findings, this suggests that the slow
defecation phenotype of clk-1 mutants might be due to their
elevated mitochondrial ROS production. In order to test this
further we treated clk-1 mutants with the antioxidant N-acetyl-
cysteine (NAC) a commonly used hydrophilic antioxidant, which
can reduce mitochondrial ROS production [18]. We found that
NAC treatment could partially suppress the slow defecation cycle
in a dose-dependent manner (Figure 4B). Complete suppression
could not be obtained because higher levels of the compound was
toxic, possibly because of inhibition of normal ROS levels in other
compartments. Finally, to test whether the increased mitochon-
drial oxidative stress is the cause of the deregulated metabolism of
the BA-like molecules we tested whether the tat-2(qm179) mutation
could suppress the effect of antioxidant treatment. We found that
treatment with 10 mM NAC was without effect on tat-2; clk-1
(Figure 4C and Table S1), indicating that tat-2(qm179) is epistatic
Figure 2. clk-1 mutants are sensitive to the availability of endogenous BA–like molecules and to exogenous mammalian BAs. The bars
represent the mean defecation cycle length of animals that had been scored for three consecutive cycles for clk-1(qm30) and isp-1(qm150) and for five
consecutive defecation cycles for all other genotypes. (A) The BA-binding resin cholestyramine partially suppresses the slow defecation of clk-1 mutants
but is without effect on the wild type as well as on the mitochondrial mutant isp-1(qm150) (n$50 for each genotype). (B) clk-1(qm30) mutants are
sensitive to exogenous BAs, which enhance the clk-1 phenotype (n$20 animals). (C) Cholic acid (CA), a relatively hydrophilic BA, suppresses clk-1 at very
low concentration but enhances the phenotype at higher concentration. Chenodeoxycholic acid (CDCA) a relatively hydrophobic BA is without effect at
0.15 mM but enhances the phenotype at higher concentrations. All effects depend on the presence of cholesterol as they are totally or mostly (at
2.5 mM CDCA) abolished in the absence of cholesterol supplementation. The asterisks represent p values obtained by t-test comparing the defecation
cycle after various treatments to that observed with 0.25% DMSO only. All treatments in the absence of cholesterol were indistinguishable from 0.25%
DMSO exceptat2.5 mMCDCA which was significantlysloweratP,0.001; (n$40animals foreach condition). (D)Etherextracts from thewild type or clk-
1 mutants enhance the defecation phenotype of clk-1 mutants but not that of the wild type in a dose-dependent manner and extracts from clk-1
mutants are approximately four times more active than extracts from the wild type. The asterisks represent t-test comparisons to the control of 0.25%
DMSO treatment(n$25 animals). (E) Thedefecation phenotype of tat-2(qm179) mutants canbe rescued by exogenous BAs but this effect is abolishedin
the absence of cholesterol supplementation. In addition, the suppression of clk-1 by tat-2 is also suppressed by BA treatment, an effect which also
requires cholesterol supplementation. BA treatment is without effect on the wild type and on dsc-4 mutants. (n$20 for each genotype and condition).
The data presented in (B) and in (E) were generated simultaneously and the data for the wild type is the same in both panels. They are presented in
separate panels for clarity. The error bars represent S.E.M. *** represents P,0.001, **represents P,0.01, *represents P,0.05.
doi:10.1371/journal.pgen.1002553.g002
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Enzyme Category
#
C. elegans
Genes
E-value from Blast Comparison
to Mouse Protein
Summary of Effect
on Defecation Rate
Effect on Defecation Rate (seconds)
(p-values vs. control*)
Cholesterol 25-hydroxylase (AAC97482) F35C8.5 3e-29 Q 218.464.1 (P,0.0001)
F49E12.10 3e-08 - +8.465.5 (P=0. 1)
F49E12.9 2e-5 - +7.865.3 (P=0.15)
3b-Hydroxy-D5-C27 steroid
oxidoreductase (AF277718_1)
hsd-1 1e-09 - 21.864.0 (P=0.67)
hsd-2 4e-07 - 24.965.3 (P=0.41)
hsd-3 2e-05 - 24.764.8 (P=0.33)
Bile acid CoA ligase (NP_036108) acs-20 e-103 Q 213.763.3 (P=0.0001)
acs-22 e-101 - +2.464.2 (P=0.57)
2-Methylacyl-CoA racemase (AAB72146) C24A3.4 5e-59 - 20.464.8 (P=0.93)
ZK892.4 3e-56 - 22.564.2 (P=0.56)
Branched-chain acyl-CoA oxidase
(CAB65251)
acox-1 e-117 - +1.164.4 (P=0.79)
F08A8.2 e-109 - 20.264.1 (P=0.97)
F59F4.1 e-107 Q 211.163.7 (P=0.005)
C48B4.1 e-105 - +2.664.2 (P=0.53)
F08A8.4 e-104 - 27.064.4 (P=0.12)
F08A8.3 e-101 - 20.266.5 (P=0.97)
D-bifunctional protein (CAA62015) dhs-28 4e-84 Q 218.864.7 (P=0.0002)
dhs-25 8e-15 - +10.366.0 (P=0.09)
F54F3.4 1e-13 - 22.166.4 (P=0.75)
Peroxisomal thiolase 2 (AAA40098) daf-22 e-134 Q 218.763.6 (P,0.0001)
nlt-1 2e-12 Q 226.764.2 (P,0.0001)
B.A. CoA:a.a. N-acyltransferase (AAB58325) W03D8.8 1e-27 - 21.963.6 (P=0.59)
C31H5.6 2e-26 - +1.664.2 (P=0.70)
K05B2.4 2e-25 - 24.766.6 (P=0.35)
T05E7.1 1e-16 - 22.664.7 (P=0.58)
D4-3-Oxosteroid 5b-reductase
(NP_663339) and 3a-Hydroxysteroid
dehydrogenase (NP_085114)
Y39G8B.1 7e-72 - +0.963.6 (P=0.80)
T08H10.1 3e-56 q +10.663.9 (P=0.008)
C07D8.6 2e-55 Q 212.864.7 (P=0.01)
ZC443.1 2e-52 - 28.764.3 (P=0.06)
Y39G8B.2 2e-47 - 24.264.9 (P=0.40)
F53F1.3 5e-39 - 25.265.6 (P=0.36)
F53F1.2 6e-38 Q 215.466.3 (P=0.02)
Cytochrome P450s cyp-13A1 n/a - 28.965.5 (P=0.12)
cyp-13A2 n/a - 22.565.5 (P=0.66)
cyp-13A3 n/a - +10.566.3 (P=0.11)
cyp-13A4 n/a Not avail.
cyp-13A5 n/a - 21.565.5 (P=0.79)
cyp-13A6 n/a - 22.865.9 (P=0.64)
cyp-13A7 n/a - 23.564.5 (P=0.44)
cyp-13A8 n/a - +2.066.8 (P=0.77)
cyp-13A10 n/a - +2.864.2 (P=0.51)
cyp-13A11 n/a - 27.665.5 (P=0.18)
cyp-13A12 n/a - 25.265.9 (P=0.39)
cyp-13B1 n/a - 27.465.8 (P=0.21
cyp-13B2 n/a - 24.366.6 (P=0.52)
cyp-14A1 n/a - +10.565.6 (P=0.07)
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Enzyme Category
#
C. elegans
Genes
E-value from Blast Comparison
to Mouse Protein
Summary of Effect
on Defecation Rate
Effect on Defecation Rate (seconds)
(p-values vs. control*)
cyp-14A2 n/a - +6.366.6 (P=0.34)
cyp-14A3 n/a - 29.564.9 (P=0.06)
cyp-14A4 n/a - 24.965.7 (P=0.40)
cyp-14A5 n/a Q 214.064.2 (P=0.002)
daf-9/cyp-22A1 n/a - 20.563.3 (P=0.87)
cyp-23A1 n/a - +7.065.3 (P=0.20)
cyp-25A1 n/a - +2.464.4 (P=0.58)
cyp-25A2 n/a - +6.366.6 (P=0.34)
cyp-25A3 n/a - +0.365.2 (P=0.96)
cyp-25A4 n/a - +6.064.9 (P=0.22)
cyp-25A5 n/a - 22.064.3 (P=0.64)
cyp-25A6 n/a - 21.063.9 (P=0.80)
cyp-29A1 n/a - +10.066.8 (P=0.16)
cyp-29A2 n/a - 22.663.9 (P=0.52)
cyp-29A3 n/a Q 213.264.0 (P=0.003)
cyp-29A4 n/a - 20.263.9 (P=0.96)
cyp-31A2 n/a - +0.664.4 (P=0.89)
cyp-31A3 n/a Q 211.064.0 (P=0.01)
cyp-32A1 n/a - +1.464.6 (P=0.75)
cyp-32B1 n/a - +6.564.5 (P=0.17)
cyp-33A1 n/a - 23.664.7 (P=0.45)
cyp-33B1 n/a - +11.865.9 (P=0.06)
cyp-33C1 n/a - 26.264.3 (P=0.16)
cyp-33C2 n/a - 24.664.1 (P=0.27)
cyp-33C3 n/a - 25.964.9 (P=0.24)
cyp-33C4 n/a - 25.063.9 (P=0.20)
cyp-33C5 n/a Q 28.063.4 (P=0.024)
cyp-33C6 n/a Q 213.163.4 (P=0.0005)
cyp-33C7 n/a - +3.464.6 (P=0.46)
cyp-33C8 n/a q +12.164.5 (P=0.01)
cyp-33C9 n/a - +7.365.1 (P=0.17)
cyp-33C11 n/a - +1.664.6 (P=0.74)
cyp-33C12 n/a - +9.865.2 (P=0.07)
cyp-33D1 n/a Q 28.963.5 (P=0.02)
cyp-33D3 n/a - 24.864.6 (P=0.31)
cyp-33E1 n/a q +12.665.4 (P=0.03)
cyp-33E2 n/a - 22.265.3 (P=0.69)
cyp-33E3 n/a - +4.066.7 (P=0.55)
cyp-34A1 n/a - +1.266.2 (P=0.84)
cyp-34A2 n/a - +0.565.7 (P=0.93)
cyp-34A3 n/a - +1.064.0 (P=0.80)
cyp-34A4 n/a Q 214.564.7 (P=0.003)
cyp-34A5 n/a - +2.464.6 (P=0.61)
cyp-34A6 n/a Q 211.565.0 (P=0.03)
cyp-34A7 n/a - +1.164.2 (P=0.80)
cyp-34A8 n/a - +5.664.4 (P=0.22)
cyp-34A9 n/a Q 212.565.2 (P=0.02)
cyp-34A10 n/a - +3.764.5 (P=0.41)
cyp-35A1 n/a - +4.666.3 (P=0.48)
cyp-35A2 n/a - 22.965.8 (P=0.62)
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mitochondrial oxidative stress being the primary cause of the
deregulation of the metabolism of the BA-like molecules observed
in clk-1 mutants.
Mitochondrial oxidative stress is responsible for the
increased level of activity in lipid extracts from clk-1
mutants
The hypothesis suggested by the results described so far is that
the clk-1 defecation phenotype is the result of increased
mitochondrial oxidative stress in these mutants, which increases
the level of activity of BA-like molecules. We tested this hypothesis
directly by producing and testing lipid extracts from clk-1 mutants
treated with NAC and from clk-1(qm30);sod-2(ok1030) double
mutants (Figure 5). NAC treatment reduced the level of the
activity found in the extract, and the extract from clk-1;sod-2
double mutants contained substantially higher level of activity than
the clk-1 extract. For an unknown reason the clk-1;sod-2 extract was
the most variable in terms of its activity on individual worms
(Figure 5 and Table S1).
Discussion
Here we have shown that: 1) clk-1 mutants are suppressed by
mutations of TAT-2, the worm orthologue of an ATPase that is
necessary for BA secretion in mammals, 2) the suppression by tat-2
canbe rescued by exogenous BAs, 3) RNAi knockdown of severalC.
elegans enzymes homologous to those that are implicated in BA
synthesis in mammals suppress the clk-1 phenotype, but not the
knockdown of some of the enzymes known to be necessary for
dafachronic acid synthesis, 4) clk-1 mutants display a cholesterol-
dependent sensitivity to exogenous BAs, as well as a sensitivity to
cholestyramine, a drug that sequesters BAs, 5) clk-1 mutants but not
the wild type are sensitive to an activity contained in lipid extracts
from worms, 6) the clk-1 defecation phenotype is suppressed by a
mutation in daf-36, which encodes a cholesterol 7-desaturase,
suggesting that the activity is a cholesterol derivative, 7) clk-1
mutants contain more of this activity, 8) the level of the activity is
altered by mitochondrial oxidative stress, 9) clk-1 mutants have a
deregulated cholesterol metabolism, as indicated by the fact that
their phenotype can be affected by reducing or increasing the level
of dietary cholesterol and that they accumulate more cholesterol
than the wild type when supplied with high levels of dietary
cholesterol, 10) clk-1 and tat-2 interact in determining cholesterol
content as, in contrast to what is observed in the wild type, the
cholesterol content of clk-1;tat-2 is similar at all levels of dietary
cholesterol supplementation. This last observation suggests that the
abnormal cholesterol metabolism is caused by the deregulated
metabolism of the BA-like molecules that are affected by clk-1 and
tat-2. Together all these observations imply that there are BA-like
molecules involved in cholesterol uptake in C. elegans, but also that
these molecules are likely to be structurally similar to BAs, as their
biosynthesis and secretion are affected by activities that are known
to affect BAs in mammals.
The results summarized in the previous paragraph lead to a
model of regulatory relationships between cholesterol availability,
cholesterol uptake, the synthesis and secretion of BA-like
molecules, and LDL-like lipoprotein synthesis and secretion in C.
elegans (Figure 6). All our findings appear to be remarkably
consistent with what is known about the synthesis and regulation
of BAs and LDL in vertebrates. Thus we propose that secreted
BA-like molecules participate in cholesterol uptake and that the
function of TAT-2 is required for their secretion. Cholesterol is
used in the synthesis of the BA-like molecules and, as in mammals,
the BA-like molecules act directly on cholesterol uptake but also as
signalling molecules that positively regulate the synthesis of LDL-
like lipoproteins. The core of our model is that CLK-1, via its
effect on limiting mitochondrial ROS generation, is required for a
negative feedback mechanism that down-regulates the synthesis
of the BA-like molecules as a function of cholesterol uptake. In
the absence of CLK-1 more BA-like molecules are synthesized
Table 1. Cont.
Enzyme Category
#
C. elegans
Genes
E-value from Blast Comparison
to Mouse Protein
Summary of Effect
on Defecation Rate
Effect on Defecation Rate (seconds)
(p-values vs. control*)
cyp-35A3 n/a - 23.965.2 (P=0.46)
cyp-35A4 n/a Q 212.964.1 (P=0.004)
cyp-35A5 n/a - +5.066.8 (P=0.47)
cyp-35B1 n/a - +9.366.9 (P=0.19)
cyp-35B2 n/a - +1.766.6 (P=0.80)
cyp-35B3 n/a - +12.167.0 (P=0.1)
cyp-35C1 n/a - +10.766.6 (P=0.12)
cyp-35D1 n/a - 21.366.6 (P=0.84)
cyp-36A1 n/a - +3.565.3 (P=0.51)
cyp-37A1 n/a q +14.465.4 (P=0.01)
cyp-37B1 n/a - +8.764.4 (P=0.06)
cyp-42A1 n/a - 22.864.4 (P=0.52)
cyp-43A1 n/a - +4.767.0 (P=0.51)
cyp-44A1 n/a - +0.663.5 (P=0.86)
To identify C. elegans genes involved in BA synthesis, we carried out Blast homology searches for the translated products of mouse genes known to be involved in the
process. In one case, the Blast results of two mouse proteins (NP_663339 and NP_085114) identified the same in worm homologues. The most homologous genes
(shown in the ‘‘C. elegans genes’’ column) were tested by treatment of clk-1(qm30) mutants with RNAi against these genes. All cytochrome P450s were screened as they
are highly similar to each other. The defecation rates are given as means 6 S.E.M.
#The accession numbers of the proteins used for the search are given.
*The p-values were obtained by comparing to control clk-1 mutants grown in parallel on HT115 bacteria harbouring only the empty pPD129.36 vector.
doi:10.1371/journal.pgen.1002553.t001
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measured in the wild type and in clk-1 mutants previously grown under different regimes of cholesterol supplementation. High level of cholesterol
supplementation induced greater cholesterol content than lower levels in all genotypes except clk-1; tat-2. High level of cholesterol supplementation
produced the highest cholesterol content in clk-1 mutants, an effect that was fully suppressed by tat-2 in clk-1; tat-2 mutants. In general the
cholesterol content of clk-1; tat-2 was high and independent of cholesterol supplementation. Error bars represent the standard errors of the means
across repeated experiments (n$16). Each sample represented 1000 worms and was measured three times. Cholesterol levels are shown as
normalized to the wild type level under 5 mg/ml supplementation. The wild type level was 0.056 mM. *** represents P#0.001 for t-test comparison as
indicated, #represents P,0.001 for t-test comparisons to the wild type cholesterol content at the same level of cholesterol supplementation. Table
S2 lists all numerical values and further statistical tests. (B) The slow defecation phenotype of clk-1(qm30) mutants is sensitive to both low and high
cholesterol supplementation. The phenotype is suppressed by low and enhanced by high supplementation. The sensitivity to high supplementation
is suppressed by tat-2(qm179) in clk-1; tat-2 double mutants. tat-2(qm179) attenuates the effects that different levels of supplementation have on clk-
1. The bars represent the means of the defecation cycle lengths of n$25 animals, each scored for three consecutive defecation cycles for the clk-
1(qm30) mutants and for five consecutive defecation cycles for all other genotypes. The error bars represent the standard error of the mean. The
asterisks indicate for each genotype whether the defecation cycle length with low or high cholesterol supplementation is significantly different from
that with the standard level of cholesterol by a t-test. *** represents P#0.0001.
doi:10.1371/journal.pgen.1002553.g003
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PLoS Genetics | www.plosgenetics.org 11 March 2012 | Volume 8 | Issue 3 | e1002553Figure 4. clk-1 mutants are sensitive to alterations in ROS metabolism. The bars represent the mean defecation cycle length of animals that
were scored for one cycle. (A) RNAi mediated knock-down of the mitochondrial localized superoxide dismutases SOD-2 and SOD-3 enhance the slow
defecation cycle phenotype of clk-1 mutants (n$6 for each genotype). (B) NAC (N-acetyl cysteine) supplementation suppresses the slow defecation of
clk-1 mutants at 8 and 10 mM concentrations (n$22 for each genotype). (C) Treatment with 10 mM NAC is without effect on tat-2; clk-1 double
mutants (n$6 for each genotype). The error bars represent S.E.M. *** represents P,0.001, **represents P,0.01, *represents P,0.05.
doi:10.1371/journal.pgen.1002553.g004
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increased synthesis of the BA-like molecules up-regulates the level
of LDL-like lipoprotein synthesis and secretion, which in turn
determines the length of the defecation cycle.
Our data show that availability of BA-like molecules and the
rate of defecation are tightly linked as shown by the sensitivity of
the mutant defecation cycle to BA supplementation, sequestration
of the BA-like molecules, and the inhibition of the synthesis of the
BA-like molecules. The hypothesis that CLK-1 is necessary for a
feed-back from cholesterol uptake to the synthesis of the BA-like
molecules provides the link between the level of cholesterol
supplementation and the level of the BA-like molecules (and thus
between the level of cholesterol supplementation and defecation)
(Figure 6). However, the model cannot accurately predict the
effect of mutations on the level of whole-animal cholesterol.
Indeed, the level of cholesterol likely depends on cholesterol flux
through the entire organism. This is determined by a number of
factors that we cannot precisely quantify at this stage, including the
exact quantitative relationship between the level of cholesterol
uptake and the level of synthesis of the BA-like molecules via the
CLK-1-dependent mechanism, the level of cholesterol loss
through the synthesis of BA-like molecules if these are cholester-
ol-derived, and the loss of the BA-like molecules through secretion,
the level of cholesterol loss through LDL-like lipoprotein secretion
(whose target in the organism is unknown), the level of cholesterol
loss through yolk synthesis and egg-laying, and in fact any other
form of cholesterol elimination or storage, whether or not
regulated by the BA-like molecules.
Suppression of the clk-1 defecation phenotype can be obtained by
knocking down the enzymes necessary for peroxisomal b-oxidation
that in mammals are necessary for shortening the side-chain of
cholesterol (Table 1). This suggests that if the C. elegans BA-like
molecules are cholesterol derived they might have a shortened side-
chain. This is in contrast to dafachronic acid (Figure S1), which is a
steroid that acts as a hormone that regulates development in C.
elegans [35]. We have not yet tested if the BA-like molecules can
affect other clk-1 phenotypes in addition to defecation, such as slow
aging. More detailed structural information on the C. elegans BA-like
molecules,and possiblytheavailabilityofsyntheticmolecules,might
be necessary to test rigorously their effect on phenotypes that are
harder to quantify than defecation.
The suppressive effect of cholic acid (CA) at very low
concentrations is difficult to explain unless the BA-like molecules
are indeed structurally similar to BAs. However, if this is the case
the observed effect might result from the dilution by CA of the
native and potentially more hydrophobic BA secreted by worms.
However, as CA serves as negative feedback for BA synthesis and
secretion in mice [36], it is possibly that it could carry out a similar
role in C. elegans, which would provide an alternative explanation
for its paradoxical action at low concentration. If this is the case,
further study of this phenomenon might help in identifying the
nuclear hormone receptors (NHRs) through which the C. elegans
Figure 5. The activities of endogenous BA–like molecules are altered by mitochondrial ROS levels. The bars represent the mean
defecation cycle lengths. As before (Figure 2D), we find that clk-1 mutant lipid extracts contain more activity than the wild type. However, treatment
with NAC lowers the activity level to that of the wild type extract, and the extract from clk-1; sod-2 double mutants has much more activity than the
extract from clk-1 single mutants. All extracts are without effect on the wild type. The asterisks represent t-test comparisons to the control of 0.25%
DMSO treatment (n$25 animals). The error bars represent S.E.M. *** represents P,0.001, **represents P,0.01, *represents P,0.05.
doi:10.1371/journal.pgen.1002553.g005
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already identified a number of nuclear hormone receptor loci
whose down-regulation suppresses clk-1 mutants (not shown). One
or several of these could be the receptors for the BA-like molecules.
The metabolic syndrome is a collection of age-associated disease
risk factors that includes obesity, insulin resistance, hypertension
and dyslipidemia. Oxidative stress, which is well known to increase
with age and in obese individuals [37], has been implicated in most
of the components of the metabolic syndrome and might be the
common link between them [38,39,40]. Our findings with C. elegans,
where there appears to be BA-like molecules whose synthesis,
secretion and activity shares strong similarities with BAs in
mammals, suggest that mitochondrial oxidative stress can lead to
deregulation of BA synthesis. Abnormal BA levels in turn could lead
to metabolic disease processes via the action of BAs on sterol, lipid
and glucose metabolism by signalling through BA receptors.
Interestingly, the possibility of an involvement of oxidative stress
on the regulation of BA synthesis and thus on the consequences of a
deregulation of this process has not yet been explored in mammals.
Materials and Methods
General methods
Fourth larval stage (L4) animals were transferred to the test plates
and grown at 20uC. The effects of the different cholesterol
concentrations or compounds were scored after raising the worms
on the test plates for one generation. Defecation cycle rates were
measured as previously described [22], at 20uC for all experiments
exceptforthe RNAiandantioxidanttreatments forwhich25uCwas
used. Compounds (cholestyramine, mixed bile acids, cholic acid,
andchenodeoxycholicacidweretestedbyspreadingthemonplates,
except that N-acetyl-L-cysteine was added to the nematode growth
media (NGM) prior to pouring it into plates. See also Text S1.
Positional cloning of dsc-3(qm179)
dsc-3 had previously been mapped to LG IV, between unc-33
and dpy-4 [22]. By using 2-point and 3-point mapping strategies,
the genetic position of qm179 was refined to a position between the
two cloned gene dpy-13 and unc-5. Due to the incomplete cosmid
coverage of the tat-2 gene, no cosmid that spans this region can
rescue the qm179 mutants. Therefore qm179 mutants were rescued
by injecting two partially overlapping PCR fragments of tat-2
genomic DNA (from 23123 to +7277 and from +7252 to +13567,
which includes the UTRs) for in vivo recombination. Two other
mutations allelic to qm179 had been originally identified, qm180
and qm184 [22]. The lesion in qm184 was identical to the qm179
lesion, and the lesion in qm180 was not found in the tat-2 exonic
sequences. The tat-2(tm1634) allele was obtained from the
National Bioresource Project and outcrossed three times. See also
Text S1.
Figure 6. Schematic representation of the biosynthetic and regulatory interactions relating cholesterol uptake and bile acid (BA)
biosynthesis and secretion to the biosynthesis and secretion of LDL-like lipoproteins. See Discussion for further explanation.
doi:10.1371/journal.pgen.1002553.g006
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The tat-2 transcriptional reporter, Ptat-2::gfp (pCDB898) was
used as backbone to build the Ptat-2::mAtp8b1, Ptat-2::mAtp8b1
A705T, Ptat-2::mAtp8b1 G308V clones. The PCR product of 3.4 kb
upstream of the initiating ATG of tat-2 was cloned into the PstI
and SmaI sites of the pPD95_77 vector. The full length of mouse
Atp8b1 cDNA was amplified from the RIKEN clone F830210O18.
To construct Ptat-2::tat-2::gfp (pCDB902) a 3945 bp long wild type
tat-2 cDNA containing 22 exons was inserted into the SmaI site of
pCDB898. To construct Pges-1::tat-2::gfp, Psth-1::tat-2::gfp,a n dPpgp-
12::tat-2::gfp, (pCDB906, pCDB905 and pCDB904, respectively) the
tat-2 promoter of pCDB902 was replaced by PCR products of 2 kb
upstream of the ges-1 initiation codon, 1.6 kb upstream of the sth-1
initiation codon or 2.7 kb upstream of the pgp-12 initiation codon.
These constructs were injected into clk-1; tat-2(qm179) mutants at a
concentration of 0.1 ng/ml along with the transformation marker ttx-
3::gfp at a concentration of 200 ng/ml. See also Text S1.
Total cholesterol content
Lipids were extracted following [41], and the cholesterol
content was determined with a kit (10007640) from Cayman
Chemical. The final concentration of Triton X-100 in each sample
was 0.5%. We also measured the volumes of young adults for all
genotypes as previously described [42], and no difference from the
wild type was found (data not shown). See also Text S1.
Active lipid extracts
The lipid extracts were prepared as previously described [31] and
re-suspended in DMSO. To assay the activity of extracts from the
wild type, clk-1(qm30), clk-1(qm30); sod-2(ok1030) or clk-1 mutants
treated with NAC, 36 ml of DMSO-dissolved extract (or 36 mlo f
DMSO ascontrol)wasspreadonto5 cmplates.Phenotypesofadult
progeny were measured after raising L4 animals on the test plates
for one generation. Due to the sensitivity of clk-1 mutants to dietary
cholesterol level, we measured and calculated that the final
concentrations of extracts applied to the plates contained less than
0.1 mg/ml of cholesterol, which cannot therefore be responsible for
any of the effects observed (Figure 2D). See also Text S1.
RNAi feeding
5–10 clk-1(qm30) hermaphrodites L4 larvae were picked to
RNAi plates. For the following 3 days, worms were transferred to
new RNAi plates to rid of contaminating OP50 bacteria. Progeny
worms were grown to the L4 stage and were then picked to new
RNAi plates for scoring. 18 hours later, they were transferred to
25uC. After two hours of acclimation, their defecation phenotype
was scored. We used 25uC for all RNAi experiments, except those
shown in Figure 1C, because the responses tend to be more robust
[22]. For each RNAi clone, five worms were scored for one
defecation cycle. Clones that had a significant effect on defecation
rate were re-screened 2–3 times.
Supporting Information
Figure S1 The structures of (A) cholesterol, (B) chenodeoxy-
cholic acid (CDCA), (C) cholic acid (CA), and (D) dafachronic
acid.
(PDF)
Figure S2 The expression pattern of the translational fusion
reporter tat-2::gfp. The expression of TAT-2 was first detected in
first larval stage worms (L1) in the intestine. From the L4 stage on
through adulthood, the strongest GFP fluorescence could be
detected in the intestine (A), the excretory canal cell (A) and the
spermatheca (D–E). However, expression was also seen in the
pharyngeal procorpus, the excretory gland cell, the pharyngeal-
intestinal valve, and the rectal gland cell (A–C). During the L4
stage, the signal was also seen in vulva cells and, around the timing
of the first ovulation, it is also expressed in the proximal gonad (D).
Scale bar: 100 mm (A) or 10 mm (B–E).
(PDF)
Table S1 All individual defecation experiments and statistics.
(PDF)
Table S2 Measurements of total cholesterol contents and
statistics.
(PDF)
Text S1 Supporting extended materials and methods.
(PDF)
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